{
     "PMID": "25024312",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20150723",
     "LR": "20141014",
     "IS": "1875-8908 (Electronic) 1387-2877 (Linking)",
     "VI": "42",
     "IP": "4",
     "DP": "2014",
     "TI": "Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease.",
     "PG": "1209-20",
     "LID": "10.3233/JAD-140444 [doi]",
     "AB": "The amyloid-beta protein precursor/presenilin 1 (AbetaPP/PS1) mouse model of Alzheimer's disease (AD) has provided robust neuropathological hallmarks of familial AD-like pattern. AD is a neurodegenerative process that causes severe cognitive impairment; it is characterized by the accumulation of amyloid-beta (Abeta) and hyperphosphorylated tau forms and by oxidative and inflammatory processes in brain. Currently, efforts are made to understand biochemical pathways because there is no effective therapy for AD. Resveratrol is a polyphenol that induces expression and activation of several neuroprotective pathways involving Sirtuin1 and AMPK. The objective of this work was to assess the effect of oral resveratrol administration on AbetaPP/PS1 mice. Long-term resveratrol treatment significantly prevented memory loss as measured by the object recognition test. Moreover, resveratrol reduced the amyloid burden and increased mitochondrial complex IV protein levels in mouse brain. These protective effects of resveratrol were mainly mediated by increased activation of Sirtuin 1 and AMPK pathways in mice. However, an increase has been observed in IL1beta and TNF gene expression, indicating that resveratrol promoted changes in inflammatory processes, although no changes were detected in other key actors of the oxidative stress pathway. Taken together, our findings suggest that resveratrol is able to reduce the harmful process that occurs in AbetaPP/PS1 mouse hippocampus, preventing memory loss.",
     "FAU": [
          "Porquet, David",
          "Grinan-Ferre, Christian",
          "Ferrer, Isidre",
          "Camins, Antoni",
          "Sanfeliu, Coral",
          "Del Valle, Jaume",
          "Pallas, Merce"
     ],
     "AU": [
          "Porquet D",
          "Grinan-Ferre C",
          "Ferrer I",
          "Camins A",
          "Sanfeliu C",
          "Del Valle J",
          "Pallas M"
     ],
     "AD": "Seccio de Farmacologia, Departament Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Institut de Biomedicina, Universitat de Barcelona, Barcelona, Spain Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. Seccio de Farmacologia, Departament Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Institut de Biomedicina, Universitat de Barcelona, Barcelona, Spain. Institut de Neuropatologia de l'Hospital Universitari de Bellvitge, Institut d'Investigacio Biomedica de Bellvitge, Universitat de Barcelona, Bellvitge, Spain Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. Seccio de Farmacologia, Departament Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Institut de Biomedicina, Universitat de Barcelona, Barcelona, Spain Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. Institut d'Investigacions Biomediques de Barcelona, CSIC, IDIBAPS, Barcelona, Spain. Seccio de Farmacologia, Departament Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Institut de Biomedicina, Universitat de Barcelona, Barcelona, Spain Grup de Neuroplasticitat i Regeneracio, Institut de Neurociencies i Departament de Biologia Cellular, Fisiologia i Immunologia, Universitat Autonoma de Barcelona, Bellaterra, Spain Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain. Seccio de Farmacologia, Departament Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Institut de Biomedicina, Universitat de Barcelona, Barcelona, Spain Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "J Alzheimers Dis",
     "JT": "Journal of Alzheimer's disease : JAD",
     "JID": "9814863",
     "RN": [
          "0 (APP protein, human)",
          "0 (Amyloid beta-Protein Precursor)",
          "0 (Neuroprotective Agents)",
          "0 (PSEN1 protein, human)",
          "0 (Presenilin-1)",
          "0 (Stilbenes)",
          "Q369O8926L (resveratrol)"
     ],
     "SB": "IM",
     "MH": [
          "Administration, Oral",
          "Alzheimer Disease/*drug therapy/pathology/physiopathology/psychology",
          "Amyloid beta-Protein Precursor/genetics/metabolism",
          "Animals",
          "Brain/drug effects/pathology/physiopathology",
          "Disease Models, Animal",
          "Male",
          "Memory Disorders/pathology/physiopathology/*prevention & control",
          "Memory, Short-Term/drug effects/physiology",
          "Mice, Transgenic",
          "Neuroprotective Agents/*pharmacology",
          "Plaque, Amyloid/drug therapy/pathology/physiopathology",
          "Presenilin-1/genetics/metabolism",
          "Recognition (Psychology)/drug effects/physiology",
          "Stilbenes/*pharmacology"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "AMPK",
          "inflammation",
          "mitochondria",
          "resveratrol",
          "sirtuin 1"
     ],
     "EDAT": "2014/07/16 06:00",
     "MHDA": "2015/07/24 06:00",
     "CRDT": [
          "2014/07/16 06:00"
     ],
     "PHST": [
          "2014/07/16 06:00 [entrez]",
          "2014/07/16 06:00 [pubmed]",
          "2015/07/24 06:00 [medline]"
     ],
     "AID": [
          "W38X646305516H65 [pii]",
          "10.3233/JAD-140444 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Alzheimers Dis. 2014;42(4):1209-20. doi: 10.3233/JAD-140444.",
     "term": "hippocampus"
}